Venn Biosciences Corporation
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Venn Biosciences Corporation - overview
Established
2017
Location
San Francisco, CA, US
Primary Industry
Healthcare Specialists
About
Founded in 2017 and based in California, US, Venn Biosciences Corporation is building a liquid-biopsy solutions platform. The company was founded by CEO Aldo Carrascoso. In August 2021, Venn Biosciences raised USD 201 million in Series C funding co-led by Heritage Provider Network, Highside Capital Management, Irving Investors, and SoftBank Group. The company utilizes a proprietary glycoproteomics biomarker interrogation platform using AI and mass spectrometry for next-gen precision medicine.
Venn Biosciences is also working to find new solutions in ovarian, pancreatic, liver, prostate, and kidney cancer, together with solutions for treatment and monitoring, immune profiling, patient stratification, and disease progression. The company is using AI-powered software for glycoprotein analysis, biomarker research, liquid-biopsy assay development, and new drug target discovery. The company plans to use its funding from August 2021 to accelerate the development and commercialization of Dawn™, the company’s liquid biopsy assay for immune checkpoint inhibitor response prediction, and to expand the network of partners on the company’s AI-driven glycoproteomics platform.
Current Investors
True Ventures, Amplify Partners, Boost VC
Primary Industry
Healthcare Specialists
Sub Industries
Biotechnology, Oncology/Cancer Treatment, Pharmaceutical Research & Development, Medical Software
Website
www.intervenn.bio
Verticals
Artificial Intelligence, Artificial Intelligence
Company Stage
Series C
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.